Meanwhile, Merck has been in discussions about potentially acquiring MoonLake Immunotherapeutics, a Swiss biotech firm, for over $3 billion, although initial offers were declined. The possible acquisition aligns with Merck's strategy to enhance its drug pipeline through strategic acquisitions. Additionally, Goldman Sachs reaffirmed its Buy rating for Merck, following the company's presentation of its expansive oncology strategy at the American Society of Clinical Oncology event. The strategy includes more than 60 registrational trials, with significant commercial opportunities projected from its antibody-drug conjugates programs. At Merck's recent annual meeting, shareholders approved all board nominees and executive compensation, while rejecting proposals for a human rights impact assessment and a tax transparency report.